COHANCE - Cohance Lifesciences

Cohance Lifesciences

COHANCE · Pharma > Pharmaceuticals & Drugs · Chairman: Venkateswarlu Jasti · MD: Venkateswarlu Jasti · Listing date: March 10, 2020 · Employees: 1114 · Hyderabad · http://www.suvenpharm.com

Stock Price vs Company Growth

2.3%

2.0%

3.1%

8.2%

47.9%

49.4%

3.7%

all

17.1%

🤔 How to analyze this graph?

Last Traded Price

₹ 455 2.3%

403

488

Company Overview

Sales

2,142 Cr

Growth: -5.1%

Profit after Tax

106 Cr

Growth: -40.7%

Mid Cap

17,408 Cr

P/E: 166.1x

Industry P/E: 31.7x

Fundamentals

Sales (Cr)	₹ 2,142
Growth	-5.1%
EBITDA	14.8%
P/S	8.1x
Dividend	0.0%
P/E	166.1x
Book Value	₹ 102
PEG Ratio	-32.9x
ROE	3.7%
P/B	4.5x

Shareholding Pattern

Institutions

Uti Small Cap Fund

2.17 %

L And T Mutual Fund Trustee Ltd-L And T Mid Cap Fund

1.95 %

Promoters

Jasti Property And Equity Holdings Private Limited(Initscapacityassoletrusteeofjastifamilytrust)

60.0 %

Others

Rambabu Chirumamilla

2.14 %

Qualified Institutional Buyer

0.7 %

Iepf

0.14 %

Increase Decrease No change

Company Profile Detailed

The company is a fully integrated global CDMO, partnering with leading innovators across the entire product lifecycle- from route scouting and early development to commercial manufacturing. With advanced capabilities in oligonucleotides, bioconjugation and complex small molecules, it addresses some of the most challenging chemistries in the industry.

Belongs to (30 Indices) view more

Investors (35)

landt.mu...

marshall...

hdfc.mut...

Followers (4)

ramakris...

krishna5...

venkatja...